about
IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndromeEmerging drugs for Guillain-Barré syndromeGuillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosisGuillain-Barré syndrome and variantsAcupuncture for Guillain-Barré syndromeIntravenous immunoglobulin for Guillain-Barré syndromePharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndromeCorticosteroids for Guillain-Barré syndromeTreatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviewsIntravenous immunoglobulin for Guillain-Barré syndromePlasma exchange for Guillain-Barré syndromeMultidisciplinary care for Guillain-Barré syndromePharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndromePharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain Barré syndromeCorticosteroids for Guillain-Barré syndromeAcupuncture for Guillain-Barré syndromeCorticosteroids for Guillain-Barré syndromeRole of cytokines and Toll-like receptors in the immunopathogenesis of Guillain-Barré syndromeEpidural morphine analgesia in Guillain Barré syndromeMore severe manifestations and poorer short-term prognosis of ganglioside-associated Guillain-Barré syndrome in Northeast ChinaPandemic A/H1N1 2009 influenza vaccination, preceding infections and clinical findings in UK children with Guillain-Barré syndrome.Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.A study of Guillain-Barré syndrome with reference to cranial neuropathy and its prognostic implication.Guillain-Barré syndrome: natural history and prognostic factors: a retrospective review of 106 casesEpidemiology of childhood Guillan-Barre syndrome in the north west of Iran.Prominent plasmacytosis following intravenous immunoglobulin correlates with clinical improvement in Guillain-Barré syndrome.Study of interleukin-6 and interleukin-8 levels in patients with neurological manifestations of dengueAcute neuromuscular respiratory paralysis.Prevalence of anti-ganglioside antibodies and their clinical correlates with guillain-barré syndrome in Korea: a nationwide multicenter study.Treatment of peripheral neuropathiesDiagnosis of Guillain-Barré syndrome in children and validation of the Brighton criteriaA prospective study of acute idiopathic neuropathy. II. Antecedent eventsCirculating Th17, Th22, and Th1 cells are elevated in the Guillain-Barré syndrome and downregulated by IVIg treatments.The treatment of inflammatory polyneuropathy by plasma exchange.Intact thumb reflex in areflexic Guillain Barré syndrome: A novel phenomenon.Guillain-Barre syndrome: Demographics, clinical profile & seasonal variation in a tertiary care centre of central India.Severity and patterns of blood-nerve barrier breakdown in patients with chronic inflammatory demyelinating polyradiculoneuropathy: correlations with clinical subtypes.Identification of gene networks and pathways associated with Guillain-Barré syndrome.Early recognition of poor prognosis in Guillain-Barre syndromeAntibodies to heteromeric glycolipid complexes in Guillain-Barré syndrome.
P2860
Q21296685-33EF78A1-AF01-4F0C-A400-FEB1C6B5FC16Q22241376-2EDC4912-F590-4794-8A55-ECAA62B24816Q22251013-D6C876A3-F7C8-4AA2-B32C-8DE95B292549Q22252353-AE200F35-B295-47F9-836F-12F60331F45AQ24187716-836FE31A-D63E-4EDA-B9E3-467DF65E0F9BQ24193522-D7F94053-2B59-4AD8-95D6-66FD93FB712FQ24200916-0FD07D54-437C-42A1-B519-6BFDE83DEB62Q24201413-428BE77B-88ED-4C04-83BA-230DC9F83E55Q24201434-439DDF67-19FC-4542-A55E-A595C245022EQ24202100-F9DE7E94-384C-442D-B0FA-96BE6316F8DBQ24202179-0103A2F1-DD32-470A-90B9-70DC4E396438Q24234676-1AB3BDDD-7C5E-4246-AF31-215B7E681603Q24235600-D34C3807-19F3-4242-8293-67FF9A009740Q24236680-FC9407ED-1253-4323-AC10-DB76A7FF6ED4Q24240016-9CD6D66C-9A2E-48A0-A29F-996ED4B5841FQ24240577-0D2908AC-9A98-44B7-B608-74EFE2C0FED8Q24246424-33C8E266-18AB-4026-9563-B3D0F905F5E7Q27027324-E6CFD08E-EE44-4460-962C-642B50091FC6Q28359678-C48C315D-B320-4419-A463-DB831584A421Q28541538-383E9222-4189-439B-B2CE-754727CF259FQ30359657-8F0538D2-B5AA-4E94-A286-9BE4C86689C0Q30397454-27E8EEF5-DFAF-4FD9-BBD9-86B8558A31E2Q30422497-74E1D88B-8F03-48C0-9160-C72A5F20C0C8Q31123673-C3C23F92-590A-4E31-B294-AB292328E5F2Q33293436-D498EF6F-D316-48C1-B0DD-F24F2E3C752CQ33332176-FF82B40D-3B10-4E50-9FDF-D674958BF29FQ33573321-581BB960-482F-4D5E-A4FC-E624DBF17F7CQ33590947-EB43636E-163A-4038-9F57-25FE09167BF2Q33594796-4D528401-AE3C-4AB3-A1A8-985014EC6A42Q33621708-8C211B33-2EC4-4F0F-A937-241C59277C77Q33627830-768BB24B-E4EB-47CF-81B3-10339F53371EQ33631049-C8F8490E-8514-4B42-9AD8-9E4C4A3FED41Q33677718-5A07E438-9CC8-43BA-A0DA-A9C3BD0DE514Q33755953-A35CBD1C-FE54-4CAF-9B92-4C135BC79F69Q33877847-CC7041C6-6649-40A5-86D1-3928690538F0Q33882766-1CC45400-9B9A-4EC4-85AC-C77E18A780D0Q34020516-D0CE2712-0FEA-4D61-A1D4-E332FFC44023Q34130447-0A1784B8-5E59-459C-8AA6-03AAD6E54211Q34686090-9630CF3C-3679-4D4B-BE70-A029EB4F7B91Q35072720-F4EF384A-AFB8-412B-A3AF-F69CB866C590
P2860
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
1978年论文
@zh
1978年论文
@zh-cn
name
Controlled trial prednisolone in acute polyneuropathy.
@en
Controlled trial prednisolone in acute polyneuropathy.
@nl
type
label
Controlled trial prednisolone in acute polyneuropathy.
@en
Controlled trial prednisolone in acute polyneuropathy.
@nl
prefLabel
Controlled trial prednisolone in acute polyneuropathy.
@en
Controlled trial prednisolone in acute polyneuropathy.
@nl
P2093
P1433
P1476
Controlled trial prednisolone in acute polyneuropathy.
@en
P2093
G D Perkin
J M Newsom-Davis
J M Pierce
R A Hughes
P304
P356
10.1016/S0140-6736(78)92644-2
P407
P577
1978-10-01T00:00:00Z